NCT03799627COMPLETEDanonymous

Phase 2, Randomized, Open-Label, Active-Controlled, Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics Study of Oral Vadadustat for the Treatment of Anemia in Hemodialysis Subjects Converting From Epoetin Alfa (FO2RWARD-2)

Sponsor

Source record

Akebia Therapeutics

Phase

Source record

Phase 2

Modality

AI-normalized

small molecule

Target

AI-normalized

Anemia in Hemodialysis Participants

Indication / condition

AI-normalized

Anemia

Intervention

Source record

Vadadustat, Epoetin Alfa, Vadadustat TIW

Related intelligence directories

Indication directory: Anemia Modality directory: small molecule Target directory: Anemia in Hemodialysis Participants

Source & freshness

Source record

NCT ID

NCT03799627

Original source

ClinicalTrials.gov

Source last updated

Sep 29, 2022

Ingested at

Jun 03, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT03799627

Title

Phase 2, Randomized, Open-Label, Active-Controlled, Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics Study of Oral Vadadustat for the Treatment of Anemia in Hemodialysis Subjects Converting From Epoetin Alfa (FO2RWARD-2)

Sponsor

Akebia Therapeutics

Status

COMPLETED

Phase

Phase 2

Condition raw

Anemia

Condition normalized

Anemia

Modality raw

Anemia

Modality normalized

small molecule

Target raw

Anemia in Hemodialysis Participants

Target normalized

Anemia in Hemodialysis Participants

Interventions

Vadadustat, Epoetin Alfa, Vadadustat TIW

Public preview

Source record

The clinical trial evaluated Vadadustat, an oral medication, for treating anemia in hemodialysis patients transitioning from Epoetin Alfa. Conducted by Akebia Therapeutics, the study aimed to determine the drug's efficacy, safety, and pharmacokinetics in maintaining hemoglobin levels within a target range.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Early access offer

Subscribe with code FOUNDERS5 for a 5-day premium trial.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

Investment-Ready Snapshot

Phase 2, Randomized, Open-Label, Active-Controlled, Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics Study of Oral Vadadustat for the Treatment of Anemia in Hemodialysis Subjects Converting From Epoetin Alfa (FO2RWARD-2)

Source & freshness

Public preview

Create an account to unlock this report

Phase 2, Randomized, Open-Label, Active-Controlled, Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics Study of Oral Vadadustat for the Treatment of Anemia in Hemodialysis Subjects Converting From Epoetin Alfa (FO2RWARD-2)

Investment-Ready Snapshot

Provenance

Protocol Description

Outcome Measures

Eligibility

Known Results And Readout Context

Patent And IP Landscape

Contacts